NASDAQ$ANAB
Anaptysbio Inc · Q4 2025 earnings
Q4 2025 earnings · · After market close · Investor relations
Briefing
AnaptysBio reported Q4 2025 net income of $49.6M ($1.79 EPS) and plans a Q2 2026 biopharma spin-off.
Fourth-quarter net income was $49.6 million ($1.79 per share) versus a loss a year ago; full-year net loss was $13.2 million ($0.46 per share). Cash and investments were about $311 million at year-end. The company is on track to spin biopharma operations into First Tracks Biotherapeutics in Q2 2026 while retaining Jemperli royalty assets. GSK reported Jemperli Q4 sales of $343 million, implying a ~$1.4B annualized run rate.
- Q4 net income $49.6M; royalty economics from Jemperli strengthening.
- Planned spin-off of biopharma into First Tracks (TRAX).
- ANB033 Phase 1b ongoing in celiac disease and EoE.
- ~$311M cash at year-end 2025.
- Peak Jemperli royalty potential >$390M at GSK peak sales guide.
Headline financials
Revenue & EPS history
Anaptysbio · Revenue · Quarterly
$108M
Forward guidance
Spin-off targeted Q2 2026; royalty company to retain Jemperli and imsidolimab economics while biopharmaCo advances ANB033, rosnilimab, and ANB101.
Tailwinds
- Jemperli commercial momentum and milestone payments.
- Value unlock via separation of royalties vs pipeline.
- Multiple immunology assets in clinic.
Headwinds
- Full-year still a net loss ex-Q4 royalty items.
- Spin complexity and Form 10 execution risk.
- Clinical-stage pipeline attrition risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2025
-1.7%
Avg return
Earnings day
-1.5%
Avg return
5 days after
-2.2%
Avg return
30 days after
51%
20 / 39 earnings
Positive
+15.8%
Q4 2019
Best reaction
-71.3%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.7% | -7.0% | -20.1% | |
| Q4 2025 | +14.5% | +13.0% | +9.2% | |
| Q3 2025 | +3.5% | -2.2% | +27.7% | |
| Q1 2025 | +0.9% | +2.6% | +18.2% | |
| Q4 2024 | +4.8% | +2.1% | +15.5% | |
| Q3 2024 | +11.4% | +6.9% | +18.7% | |
| Q2 2024 | -2.1% | +0.9% | +13.3% | |
| Q1 2024 | -9.1% | -1.9% | -9.0% | |
| Q4 2023 | +5.1% | -5.4% | -10.6% | |
| Q3 2023 | +6.0% | -0.1% | -9.3% | |
| Q2 2023 | +1.3% | +1.6% | +6.5% | |
| Q1 2023 | -9.5% | -13.3% | -12.9% | |
| Q4 2022 | -1.4% | -5.1% | -12.6% | |
| Q3 2022 | +0.7% | +6.5% | -3.0% | |
| Q2 2022 | -6.2% | +6.2% | +7.0% | |
| Q1 2022 | -11.6% | -10.1% | -14.3% | |
| Q4 2021 | -3.5% | -5.4% | -14.6% | |
| Q3 2021 | +8.9% | +2.9% | -11.2% | |
| Q2 2021 | -1.0% | +0.4% | +15.0% | |
| Q1 2021 | +3.0% | +10.5% | +0.6% | |
| Q4 2020 | +8.4% | +4.2% | -19.9% | |
| Q3 2020 | -1.5% | -0.3% | -18.7% | |
| Q2 2020 | -5.6% | -8.4% | -14.4% | |
| Q1 2020 | +0.2% | +13.0% | +10.3% | |
| Q4 2019 | +15.8% | +21.9% | -11.0% | |
| Q3 2019 | -71.3% | -69.6% | -61.2% | |
| Q2 2019 | -1.4% | -5.2% | -20.5% | |
| Q1 2019 | -6.8% | -0.7% | -3.5% | |
| Q4 2018 | -1.6% | -4.4% | +1.8% | |
| Q3 2018 | -16.1% | -19.0% | -16.5% | |
| Q2 2018 | +4.6% | +6.8% | +10.2% | |
| Q1 2018 | +0.5% | +0.6% | -18.8% | |
| Q4 2017 | -6.6% | -9.1% | -26.6% | |
| Q3 2017 | +1.3% | +2.7% | +37.1% | |
| Q2 2016 | +0.8% | -5.2% | +46.0% | |
| Q2 2017 | +0.8% | -5.2% | +46.0% | |
| Q1 2016 | -1.1% | +0.2% | -15.9% | |
| Q4 2016 | -1.1% | +7.4% | -12.4% | |
| Q1 2017 | +2.5% | +7.4% | -12.4% | |
| Q3 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro